Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE42.6700
- TODAY'S CHANGE (%)-0.7600 (-1.7499%)
- Bid / Lots42.6300/ 4
- Ask / Lots42.7600/ 4
- Open / Previous Close43.2100 / 43.4300
- Day Range
- 52 Week Range
- Volume51,176
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 726 | 43.21 |
| 09:36 ET | 100 | 42.885 |
| 09:39 ET | 100 | 42.18 |
| 09:43 ET | 867 | 42.83 |
| 09:45 ET | 562 | 42.85 |
| 09:50 ET | 500 | 43.1137 |
| 10:03 ET | 200 | 43.01 |
| 10:06 ET | 200 | 43.06 |
| 10:12 ET | 774 | 43.11 |
| 10:17 ET | 623 | 43.13 |
| 10:19 ET | 100 | 43.14 |
| 10:32 ET | 208 | 43.066 |
| 10:35 ET | 100 | 42.98 |
| 10:39 ET | 200 | 43.025 |
| 10:51 ET | 200 | 42.89 |
| 10:57 ET | 900 | 42.925 |
| 11:00 ET | 1600 | 43 |
| 11:02 ET | 300 | 43.2 |
| 11:06 ET | 200 | 43.14 |
| 11:09 ET | 100 | 43.04 |
| 11:11 ET | 300 | 43 |
| 11:18 ET | 115 | 42.93 |
| 11:20 ET | 300 | 42.9 |
| 11:22 ET | 300 | 43.01 |
| 11:24 ET | 400 | 42.93 |
| 11:26 ET | 300 | 42.955 |
| 11:31 ET | 300 | 42.905 |
| 11:38 ET | 100 | 42.86 |
| 11:42 ET | 200 | 42.81 |
| 11:44 ET | 200 | 42.76 |
| 11:45 ET | 200 | 42.75 |
| 11:47 ET | 200 | 42.62 |
| 11:49 ET | 100 | 42.66 |
| 11:51 ET | 100 | 42.58 |
| 11:56 ET | 300 | 42.58 |
| 11:58 ET | 600 | 42.585 |
| 12:00 ET | 1200 | 42.6 |
| 12:02 ET | 100 | 42.675 |
| 12:05 ET | 200 | 42.57 |
| 12:07 ET | 300 | 42.5 |
| 12:09 ET | 100 | 42.47 |
| 12:12 ET | 200 | 42.47 |
| 12:18 ET | 100 | 42.475 |
| 12:20 ET | 100 | 42.4 |
| 12:21 ET | 100 | 42.395 |
| 12:23 ET | 300 | 42.445 |
| 12:32 ET | 300 | 42.51 |
| 12:34 ET | 200 | 42.58 |
| 12:36 ET | 100 | 42.67 |
| 12:38 ET | 877 | 42.64 |
| 12:39 ET | 100 | 42.64 |
| 12:43 ET | 100 | 42.685 |
| 12:45 ET | 100 | 42.715 |
| 12:48 ET | 100 | 42.685 |
| 12:50 ET | 300 | 42.69 |
| 12:54 ET | 300 | 42.62 |
| 12:56 ET | 100 | 42.635 |
| 12:57 ET | 200 | 42.59 |
| 12:59 ET | 200 | 42.6 |
| 01:01 ET | 398 | 42.465 |
| 01:08 ET | 300 | 42.37 |
| 01:10 ET | 200 | 42.38 |
| 01:12 ET | 1500 | 42.49 |
| 01:14 ET | 210 | 42.58 |
| 01:15 ET | 100 | 42.58 |
| 01:17 ET | 200 | 42.64 |
| 01:24 ET | 200 | 42.58 |
| 01:30 ET | 400 | 42.66 |
| 01:32 ET | 437 | 42.565 |
| 01:35 ET | 600 | 42.57 |
| 01:42 ET | 600 | 42.615 |
| 01:53 ET | 200 | 42.6 |
| 01:55 ET | 100 | 42.56 |
| 01:57 ET | 100 | 42.52 |
| 02:00 ET | 100 | 42.51 |
| 02:09 ET | 100 | 42.54 |
| 02:15 ET | 100 | 42.62 |
| 02:20 ET | 300 | 42.69 |
| 02:22 ET | 445 | 42.69 |
| 02:24 ET | 200 | 42.7 |
| 02:27 ET | 200 | 42.64 |
| 02:31 ET | 500 | 42.67 |
Yesterday
May 2, 2024
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 12, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
7:13AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 10, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.3B | -15.6x | --- |
Janux Therapeutics Inc | 3.2B | -43.7x | --- |
SpringWorks Therapeutics Inc | 3.4B | -8.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
IDEAYA Biosciences Inc | 3.2B | -21.0x | --- |
Apogee Therapeutics Inc | 2.9B | -29.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -15.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
